Novocure Announces Departure of Chief Commercial Officer

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that its Chief Commercial Officer, Peter Melnyk, will be leaving the company to pursue other interests. Mr. Melnyk will continue his employment with the company until March 15, 2017 to ensure a smooth transition. “I want to thank Peter for his more than five years of …

First Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for the Treatment of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy

The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating …

Novocure to Participate in the BIO 2017 CEO & Investor Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the BIO 2017 CEO & Investor Conference on Feb. 13, 2017, in New York City. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s presentation will begin at 5 p.m. EST. The …